A carregar...
Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
Alemtuzumab, an anti-CD52 monoclonal antibody, is effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Common adverse effects include the development of autoimmune diseases, and Graves’ disease is one of the most frequent presentations. We report here a case of alemtuzumab-in...
Na minha lista:
| Publicado no: | Int J Immunopathol Pharmacol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6458661/ https://ncbi.nlm.nih.gov/pubmed/30968726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2058738419843690 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|